# OASIS-4 (NCT05587296)

> A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05587296
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bayer
- Conditions: Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Hot Flashes
- Interventions: Elinzanetant (BAY3427080); Placebo
- Enrollment: 474
- Primary outcome: Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])
- Primary outcome: Mean Change in Frequency of Moderate to Severe HFs From Baseline to Week 12 (Assessed by HFDD)

## Commentary we found

- X threads: 14
- YouTube: 8
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=oasis-4-nct05587296

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05587296", "email": "<work email>"}; the inbox owner confirms by the emailed link.